免费看裸体 视频阳春-免费看裸体 网水视频-免费看裸体 网站-免费看裸体 网站视频-免费看裸体 网站涂抹-免费看裸体 阳春

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 天美MV传媒| 国产麻豆剧传媒精品国产AV杜鹃 | 国产αV视频 | 7799精品视频天天综合在线观看 | 日韩aaa | 国产成年人 | 国产三级无码 | 波多野结av衣东京热无码专区 | 少妇高潮灌满白浆毛片免费看 | 国产成人三级无码中文在线观看 | 国产日韩a视频 | 一区二区免费视频 | 男女交配网站 | 亚洲无码久久久久 | 麻豆精品久久久久久久99蜜桃 | 午夜精品久久久久久久久噜噜 | 欧美午夜A片缴情性影院竹菊影視 | 久久久久无码 | 久久久精品人妻 | 曰韩伦理片 | 韩国三级做爰高潮HD | 日韩AV无码一区二区三区 | 一级做a爰片久久毛片A片换脸 | 无码AⅤ | 午夜福利免费体验区 | 亚洲午夜精品视频 | 亚洲视频h | 久久精品久久久 | 国产哺乳奶水91在线播放 | 亚洲成AV人片一区二区梦乃 | 国产无套内射普通话对白 | 国产女团裸体无遮挡A片 | 91干逼网| 韩国三级高潮合集 | 2025亚洲无码 | av在线无码观看 | 天天综合网,7799精品视频天天看 | 黄色网址在线观看免费 | 国产在线麻豆秘 二次苍井空 | 精品熟人妻一区二区三区四区不卡 | 丰满老熟女一级AA片色欲 |